References
- Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8
- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245
- Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care 2009;15(2 Suppl):S36-41
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636
- Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
- Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. New Engl J Med 2002;347:969-74
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494-502
- Fox KA, Anderson FA Jr, Goodman SG, et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008;5:580-9
- Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708
- Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9
- Gibson CM, Chakrabarti AK, Mega J, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013;62:286-90
- Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling. Expert Rev Pharmacoecon Outcomes Res 2010;10:259-67
- Train K. Discrete Choice Methods with Simulation. Cambridge: Cambridge University Press, 2003
- Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, eds. Applications of Simulation Methods in Environmental and Resource Economics. The Economics of Non-Market Goods and Resources: Springer-Verlag. 2005, Vol 6, p. 117-34
- Sawtooth Software I. The MaxDiff system technical paper. Sawtooth Software Technical Paper Series, 2007
- Slot KB, Berge E. Thrombolytic treatment for stroke: patient preferences for treatment, information, and involvement. J Stroke Cerebrovasc Dis 2009;18:17-22
- Sonnenberg A. Patient–physician discordance about benefits and risks in gastroenterology decision-making. Aliment Pharmacol Ther 2004;19:1247-53
- Elkin EB, Kim SH, Casper ES, et al. Desire for information and involvement in treatment decisions: elderly cancer patients’ preferences and their physicians’ perceptions. J Clin Oncol 2007;25:5275-80
- Mohamed AF, Johnson FR, Hauber AB, et al. Physicians’ stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. Eur J Gastroenterol Hepatol 2012;24:419-26
- Maddali S, Biring T, Bluhm J, et al. Institute for Clinical Systems Improvement. Antithrombotic Therapy Supplement. Updated February 2013. Available at: https://www.icsi.org/_asset/bjr47w/Antithrombo.pdf [Last accessed 1 December 2013]
- Structured Approach to Benefit–Risk Assessment in Drug Regulatory Decision-Making. Prescription Drug User Fee Act (PDUFA) V. Available at: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/default.htm [Last accessed 1 October 2013]
- Johnson FR, Desvousges WH. Estimating stated preferences with rated-pair data: environmental, health, and employment effects of energy programs. J Environ Econ Mgt 1997;34:79-99
- Maddala T, Phillips KA, Reed Johnson F. An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ 2003;12:1035-47
- Schwappach DL, Strasmann TJ. ‘Quick and dirty numbers’? The reliability of a stated-preference technique for the measurement of preferences for resource allocation. J Health Econ 2006;25:432-48
- Flynn TN, Louviere JJ, Peters TJ, et al. Estimating preferences for a dermatology consultation using best–worst scaling: comparison of various methods of analysis. BMC Med Res Methodol 2008;8:76